Everything below concerns Research chemical. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2026-06-23. Numbers and descriptions here follow the published literature rather than marketing material.
Quality assessment of Selank samples typically combines purity determination with identity confirmation and counter-ion analysis. Purity is usually reported as a percentage by chromatographic area, with values above 95 percent often quoted for research-grade material. Water content and residual solvents are checked in lyophilized batches because they affect both stability and accurate mass determination. A reported purity figure does not by itself establish that a sample is the intended sequence, so orthogonal methods are needed to rule out sequence isomers or truncation products.
Characterization of Selank in laboratory settings relies on standard peptide analytical techniques. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities and degradation products, while mass spectrometry confirms molecular identity through accurate mass measurement. Amino acid analysis and peptide sequencing verify the primary structure when reference material is unavailable. Because Selank is a short chain, fragmentation-based analysis produces a diagnostic ion pattern that supports confident identification.
Peptide stability depends strongly on temperature, moisture, and pH. Lyophilized Selank is generally most stable when stored cold and dry, with freezer temperatures commonly used for long-term storage. In solution, the compound is susceptible to hydrolysis and to microbial growth if it is not handled aseptically. The C-terminal proline-rich extension appears to slow enzymatic cleavage relative to tuftsin, though quantitative degradation rates vary with the matrix and the conditions tested. Published stability data specific to Selank remain sparse.
Selank is not a naturally occurring peptide and has no known endogenous counterpart in human physiology. Russian-language sources frequently call it TP-7, while English-language sources use the name Selank almost exclusively. Database indexing is uneven, partly because early reports appeared in regional journals that are not widely cataloged. Some summaries describe the material as a tuftsin analog and others as a synthetic heptapeptide; the labels overlap rather than conflict. Citing the primary sequence resolves ambiguity more reliably than the research or trade name alone.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, written TKPRPGP in one-letter notation. Its structure consists of the immunomodulatory tetrapeptide tuftsin, Thr-Lys-Pro-Arg, extended at the carboxyl terminus by a Pro-Gly-Pro segment. The molecular formula is commonly given as C33H57N11O9, corresponding to a monoisotopic mass near 751.4 Da and an average molecular mass near 751.9 Da. All seven residues are proteinogenic amino acids, and the molecule carries no modified side chains or non-natural linkages.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C or below | For lyophilized powder, long term |
| Common analytical method | Reverse-phase HPLC | Usually paired with mass spectrometry |
| Typical reported purity | At or above 95 percent by area | Research-grade material |
| Aqueous solubility | High | Solutions used in laboratory assays |
| Moisture sensitivity | Hydrolyzes in solution | Aseptic handling reduces degradation |
Animal studies have examined behaviour in tests of anxiety, memory retention and stress response, and several report changes in neurotrophic or neurotransmitter-related markers. The human evidence base is much smaller, consisting mainly of short trials conducted in Russia with limited reporting in English-language journals. Sample sizes are modest and outcome measures vary between studies, so the findings are best described as preliminary. Independent replication under modern trial standards has not been widely reported.
Outside its country of origin the compound is generally handled as a research chemical rather than an approved medicine. No regulatory approval from the United States Food and Drug Administration or the European Medicines Agency has been granted for human use. Identity and purity are normally checked by reverse-phase high-performance liquid chromatography, with mass spectrometry used to confirm the molecular mass. Lyophilised material is stored cold and desiccated, and repeated freeze-thaw cycles are avoided.
Published work on this peptide almost always uses intranasal delivery, with drops or a spray applied to the nasal mucosa. Some animal experiments have used subcutaneous or intraperitoneal injection, and a smaller number have compared routes directly. Oral administration is not a focus of the literature, because short peptides of this size are broken down by digestive enzymes and cross intestinal barriers poorly. How much of an intranasal dose reaches the bloodstream intact in humans remains an open question.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences as a structural analogue of tuftsin, a naturally occurring tetrapeptide fragment of the immunoglobulin heavy chain. The added Pro-Gly-Pro tail was intended to slow enzymatic degradation and extend biological activity. In Russia it is registered as an anxiolytic nasal preparation, while regulators elsewhere have not approved it for clinical use.
Proposed mechanisms centre on modulation of the GABAergic system, with reports of altered expression of genes related to GABA-A receptor subunits and changed monoamine turnover. Some studies describe inhibition of enkephalinase, the enzyme that degrades endogenous enkephalins, which may prolong opioid peptide signalling. Effects on brain-derived neurotrophic factor and on cytokine expression have also been reported. These findings come largely from animal models and small human studies, and the precise primary target remains unresolved.
Paddy Considine was cast as Viserys in October 2020 for House of the Dragon, a prequel to Game of Thrones. In an interview with Winter is Coming, showrunner Ryan Condal explained that Considine was the first choice for the role of Viserys, praising him as an "incredibly gifted actor" who had experience in "everything from comedy to dark drama". Considine was in "disbelief" upon finding out that he was being offered the role, as he believed that the entertainment industry had "at large had only ever seen him as the working-class striver he made his name playing in the 2000s". He was glad to take on the new role, as he thought himself "capable of so much more than what I was being given to play with", and felt that "he could finally showcase the full breadth of his talent." Considine used the experience of witnessing his late father's declining health from cancer as an inspiration in portraying the physical decline of a frail Viserys in "The Lord of the Tides". He described his father as dealing with "gargling sounds, fighting for breath, and... being high on painkilling drugs and things like that", and added these elements to Viserys to "imbue him with sincerity and realness". He also explained that acting as a character who is sick caused oxygen levels in his body to decrease, as he was "nearly passing out from doing those things." Considine was credited on the main cast for season 1, excluding the season finale "The Black Queen". In season 2, he made two uncredited guest appearances in the episodes "Smallfolk" and "The Red Sowing".
== Function == TIMP1 is an inhibitory molecule that regulates matrix metalloproteinases (MMPs) and disintegrin-metalloproteinases (ADAMs and ADAMTSs) through binding of the TIMP1 N-terminal domain to the metalloproteinase active site. It has also been suggested that the C-terminal domain of TIMP1 can bind to the inactive precursors pro-MMP-2 and pro-MMP-9. In regulating MMPs, TIMP1 plays a crucial role in extracellular matrix (ECM) composition, wound healing, and pregnancy. The dysregulated activity of TIMP1 has been implicated in inflammation, cancer, and fibrosis. In pregnancy, TIMP1 plays a regulatory role in the process of implantation, particularly the cytotrophoblast invasion of the uterine endometrium. Additionally, it plays a role in regulating the transcriptional profile of fetal and placental tissues associated with the early stages of pregnancy. Studies attribute this role to a mechanism involving the chromatin structure at the TIMP1 promoter region, implicating new pharmaceutical possibilities for the therapeutic regulation of TIMP1. Accordingly, TIMP1 can be manipulated in vitro using techniques, like the TIMP1 knock-out.
Even though half-lives of hundreds or thousands of years would be relatively long for superheavy elements, they are far too short for any such nuclides to exist primordially on Earth. Additionally, instability of nuclei intermediate between primordial actinides (232Th, 235U, and 238U) and the island of stability may inhibit production of nuclei within the island in r-process nucleosynthesis. Various models suggest that spontaneous fission will be the dominant decay mode of nuclei with A > 280, and that neutron-induced or beta-delayed fission—respectively neutron capture and beta decay immediately followed by fission—will become the primary reaction channels. As a result, beta decay towards the island of stability may only occur within a very narrow path or may be entirely blocked by fission, thus precluding the synthesis of nuclides within the island. The non-observation of superheavy nuclides such as 292Hs and 298Fl in nature is thought to be a consequence of a low yield in the r-process resulting from this mechanism, as well as half-lives too short to allow measurable quantities to persist in nature. Various studies utilizing accelerator mass spectroscopy and crystal scintillators have reported upper limits of the natural abundance of such long-lived superheavy nuclei on the order of 10−14 relative to their stable homologs.
A defining strength of the T32 program is its structured approach to career development. Each trainee develops an individualized training plan with guidance from a primary mentor and multidisciplinary mentoring committee. The program combines intensive laboratory research with didactic coursework, journal clubs, works-in-progress seminars, grant-writing workshops, responsible conduct of research training, scientific communication, peer-review experience, and individualized career development planning. Regular evaluations ensure that trainees achieve progressive scientific independence while developing the professional skills necessary to compete successfully for fellowships, career development awards, and independent research funding. The training environment emphasizes collaboration across basic, translational, and clinical research disciplines. Through participation in institute-wide seminars, center activities, collaborative research projects, and national scientific meetings, trainees interact with internationally recognized investigators and gain exposure to diverse scientific perspectives and emerging technologies. Access to state-of-the-art core facilities—including genomics, proteomics, metabolomics, imaging, pathology, bioinformatics, and animal model resources—provides trainees with advanced technical expertise while promoting interdisciplinary approaches to complex problems in aging research. The Barshop Institute's T32 program is distinguished by its long-standing record of success in preparing independent investigators.
=== ESI variations === There are some ESI methods that require little to no sample preparation. One such method is a method termed extractive electrospray ionization (EESI). This method involves having an electrospray of solvent directed at an angle against a different spray of the sample solution, produced by a separate nebulizer. This method requires no sample preparation in that the electrospray of solvent extracts the sample from the complex mixture, effectively removing any background contaminants. Another particularly powerful variation on ESI is desorption electrospray ionization (DESI), which involves directing an electrospray at a surface with the sample deposited on top of it. The sample is ionized in the electrospray as it splashes off the surface, then traveling to the mass spectrometer. This method is important because no sample preparation is needed for this method. A sample simply needs to be deposited on a surface, such as paper. Atmospheric pressure chemical ionization (APCI) is similar to ESI in that the sample is nebulized in droplets that are then evaporated, leaving behind a charged ion to be analyzed. APCI experiences few of the negative matrix effects experienced by ESI due to the fact that ionization occurs in the gas phase in this method rather than the within the liquid droplets as in ESI and the fact that in APCI there is an overabundance of reaction gas, thus minimizing the effect of the matrix on the ionization process.
Sources: en.wikipedia.org
== G == G3P – gall – gall-inducing insect – gamete – gametophyte – gastrula – gel electrophoresis – gene – genetic drift – gene duplication – gene pool – genetic code – genetic equilibrium – genetic fingerprint – genetic recombination – genetics – gene regulatory network – genetic carrier – gene therapy – genome – genome project – genomics – genotype – geologic time – George W. Beadle – glucose – glycolipid – glycolysis – glycome – glycomics – glycoprotein – glycoprotein – Gobind Khorana – Golgi apparatus – Gondwana – gradient – gravitational biology – gravitropism – Gregor Mendel – ground tissue – growth curve – Guthrie test
== Adverse effects == As with other drugs that inhibit the renin–angiotensin system, if candesartan is taken by pregnant women during the second or third trimester, it can cause injury and in some cases, death of the developing fetus. Symptomatic hypotension may occur in people who take candesartan and are volume-depleted or salt-depleted, as can also occur when diuretics are coadministered. Reduction in renal glomerular filtration rate may occur; people with renal artery stenosis may be at higher risk. Hyperkalemia may occur; people who are also taking spironolactone or eplerenone may be at higher risk. Anemia may occur, due to inhibition of the renin–angiotensin system. As with other angiotensin receptor blockers, candesartan can rarely cause severe liver injury.
== External links == Bispecific monoclonal antibody entry in the public domain NCI Dictionary of Cancer Terms Bispecific+antibodies at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
Patients who do not drink may require fluids by nasogastric tube. Intravenous fluids are recommended only in those who have significant dehydration due to their potential complications, including congestive heart failure.
Sources: en.wikipedia.org
The most common approach combines reverse-phase liquid chromatography with mass spectrometry. Chromatography separates the components while mass spectrometry confirms the molecular mass. Peptide sequencing or tandem mass analysis can further verify the amino acid order.
Lyophilized powder is usually kept frozen and protected from moisture. Solutions are less stable and are often used promptly or divided into aliquots to avoid repeated freeze-thaw cycles. Exact shelf-life values depend on purity and handling.
No. A purity figure derived from chromatographic area does not prove the amino acid sequence. Identity requires an orthogonal method such as mass spectrometry or sequencing. Truncated or isomerized peptides can co-elute with the target compound.
The sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, written TKPRPGP in one-letter code. It combines the tetrapeptide tuftsin with a carboxyl-terminal Pro-Gly-Pro extension. This full sequence identifies the molecule more precisely than the research name.